Nuvation Bio Inc Dossier
Qualitative Analysis
Business overview
Nuvation Bio Inc. (NYSE: NUVB) is a global biopharmaceutical company dedicated to tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Founded in 2018 by industry veteran David Hung, M.D., the company focuses on targeted therapies for molecularly defined cancer patient populations. Nuvation Bio's clinical-stage pipeline is anchored by its lead asset, taletrectinib (commercialized as IBTROZI®), an oral, potent, central nervous system (CNS)-active, and selective next-generation ROS1 inhibitor designed for ROS1-positive non-small cell lung cancer (NSCLC). Additionally, the company is advancing safusidenib, a brain-penetrant IDH1 inhibitor, and an innovative drug-drug conjugate (DDC) program.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Driving commercial adoption of IBTROZI (taletrectinib) in the U.S. for advanced ROS1-positive non-small cell lung cancer (NSCLC), with a strategic focus on transitioning patient mix toward newly diagnosed first-line (TKI-nau0000ve) patients.
Expected impact: Sustained revenue stacking and long-term product revenue growth as patients remain on therapy longer due to IBTROZI's durable response profile.
Successful completion of process technology transfer and product introduction to Thermo Fisher Scientific for the final drug product manufacturing of IBTROZI in the United States.
Expected impact: Ensures a high-quality, secure, and localized critical drug supply chain closer to U.S. patients and healthcare providers.
Advancing and expanding the pivotal Phase 3 SIGMA study (G203) evaluating safusidenib in high-grade and high-risk IDH1-mutant gliomas, including protocol amendments to add a non-pivotal single-arm cohort for grade 3 IDH1-mutant oligodendroglioma.
Expected impact: Establishes safusidenib as a second major commercial pillar targeting a large brain cancer market with high unmet needs.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Transformed Nuvation Bio into a late-stage global oncology company by adding two clinical-stage assets: taletrectinib (now approved as IBTROZI) and safusidenib (now in Phase 3).
Financial impact: All-stock transaction that preserved Nuvation's cash balance while adding immediate commercial-stage product revenue potential.
Strategic Partnerships
Acquired the Japan rights to safusidenib from Daiichi Sankyo, securing exclusive global development and commercialization rights and enabling Nuvation Bio to advance the pivotal Phase 3 SIGMA study for patients with high-risk IDH1-mutant glioma.